MNLO Menlo Therapeutics Inc.

4.99
+0.06  (+1%)
Previous Close 4.93
Open 5
Price To Book 1.03
Market Cap 119,439,472
Shares 23,935,766
Volume 18,668
Short Ratio
Av. Daily Volume 51,018

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 planned for 2019.
Serlopitant
Pruritus associated with psoriasis
Phase 3 data due 1H 2020.
Serlopitant
Pruritus associated with prurigo nodularis
Phase 2 data released October 8, 2018. Endpoints not met.
Serlopitant
Refractory chronic cough
Phase 2 data released April 9, 2018. Endpoints not met.
Serlopitant
Pruritus associated with atopic dermatitis
Phase 2 data due mid-2020.
Serlopitant
Chronic pruritus of unknown origin

Latest News

  1. Life Science Company Live Investor Presentations Now Available for On-Demand Viewing
  2. Life Science Company Live Investor Conference July 11th
  3. Is Menlo Therapeutics Inc. (MNLO) A Good Stock To Buy ?
  4. Menlo Therapeutics Announces Addition of Ronald A. Krasnow as General Counsel and Chief Compliance Officer
  5. Menlo Therapeutics to Present at Upcoming Investor Conferences
  6. EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Menlo Therapeutics, Inc. of Class Action Lawsuit
  7. Menlo Therapeutics to Present at the Class of 2018 Biotech IPOs Investor Day
  8. Consider These 3 Falling Knives
  9. Menlo Therapeutics Announces Publication of Serlopitant Phase 2 Data for the Treatment of Pruritus Associated with Prurigo Nodularis
  10. Menlo Therapeutics Announces New Board Member Elisabeth Sandoval
  11. Menlo Therapeutics to Present at the 31st Annual ROTH Conference
  12. Menlo Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
  13. INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Menlo Therapeutics, Inc. of Class Action Lawsuit
  14. Menlo Therapeutics Announces Late-Breaking Oral Presentation at the American Academy of Dermatology Annual Meeting
  15. Report: Developing Opportunities within Incyte, Burlington Stores, Hannon Armstrong Sustainable Infrastructure Capital, iRobot, Lear, and Menlo Therapeutics — Future Expectations, Projections Moving into 2019
  16. Menlo Therapeutics’ Serlopitant Granted Breakthrough Therapy Designation by FDA for the Treatment of Pruritus Associated with Prurigo Nodularis
  17. Lawsuit for Investors in NASDAQ: MNLO shares against Menlo Therapeutics Inc. announced by Shareholders Foundation